Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Semaglutide tops dulaglutide when treating patients with type 2 diabetes and CVD Weekly injections of semaglutide are associated with more significant cardiovascular benefits than dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), according to a new real-world analysis of nearly 60,000 Medicare patients
*Correspondence: Glen Arslan Lied, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Glutathione Injection Intravenous direct injection involves injecting a concentrated dose of glutathione directly into a vein
2 Experimental 2.1 Materials and apparatus Cetyltrimethylammonium bromide (98%, CTAB), triethanolamine (TEA), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), hydrochloride acid (HCl), ethanol, glutathione (GSH), N-hydroxysuccinimide, tetraethyl ortho silicate (98%, TEOS), N, N-dicyclohexyl carbodiimide (DCC), mercapto propyl trimethoxy silane (MPS), dithiothreitol (DTT), citric acid, and phosphate buffer saline (PBS, pH 7.4) were prepared from Merck Company (Darmstadt, Germany)
